[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

August 2018, Vol 4, No. 8, Pages 1035-1139

Original Investigation

Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1059-1065. doi:10.1001/jamaoncol.2018.0211

This prospective cohort study examines the association between hormone replacement therapy use after oophorectomy and risk of breast cancer among women with a BRCA1 mutation.

Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer

Abstract Full Text
free access has audio
JAMA Oncol. 2018;4(8):1066-1072. doi:10.1001/jamaoncol.2018.0644

This population-based cohort study examines the effect of multiple-gene sequencing on the experiences and treatment outcomes of patients with breast cancer.

Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1073-1079. doi:10.1001/jamaoncol.2018.0887

This analysis examines the characteristics of radiotherapy interventional trials compared with other oncological interventional trials reported in ClinicalTrials.gov from 2007 through 2017.

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1080-1084. doi:10.1001/jamaoncol.2018.1395

This cost-effectiveness analysis of data from the FLAURA randomized clinical trial evaluates the incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year of osimertinib as a first-line treatment for patients with EGFR-mutated advanced non–small cell lung cancer in the United States and Brazil.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1085-1092. doi:10.1001/jamaoncol.2018.1482

This whole-genome transcriptomic analysis uses next-generation sequencing to characterize the immune profile of premalignant lesions from a cohort of patients with Lynch syndrome.

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1093-1098. doi:10.1001/jamaoncol.2018.1660

This cross-sectional study uses demographic data, FDA drug-approval information, drug labels, and other published sources to estimate the percentage of US patients with cancer who were eligible for and benefited from genome-driven oncology from January 2006 through January 2018.

Incidence of Diabetes After Cancer Development: A Korean National Cohort Study

Abstract Full Text
free access has active quiz
JAMA Oncol. 2018;4(8):1099-1105. doi:10.1001/jamaoncol.2018.1684

This Korean national cohort study investigates whether the development of cancer is associated with increasing risk of subsequent diabetes.

Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(8):e180163. doi:10.1001/jamaoncol.2018.0163

This cohort study determines whether circulating tumor cell status is associated with radiotherapeutic benefit in terms of overall, local recurrence-free, and disease-free survival in patients with early-stage breast cancer.

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(8):e180798. doi:10.1001/jamaoncol.2018.0798

This cohort study assesses the speed with which inhibitors of programmed cell death 1 protein reached eligible patients in practice and compares the ages of patients treated in clinical practice with the ages of those treated in pivotal clinical trials.

Brief Report

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study

Abstract Full Text
open access
JAMA Oncol. 2018;4(8):1106-1110. doi:10.1001/jamaoncol.2017.4695

This analysis of data from a phase 1/2 study evaluates potential cases of isocitrate dehydrogenase differentiation syndrome among patients treated with enasidenib for relapsed/refractory acute myeloid leukemia.

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1112-1115. doi:10.1001/jamaoncol.2017.4526

This comparative study uses data from the US Food and Drug Administration Adverse Event Reporting System database to investigate the association between treatment with nivolumab in combination with epidermal growth factor receptor-tyrosine kinase inhibitors and interstitial pneumonitis in patients with non–small cell lung cancer.

Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer

Abstract Full Text
free access online only
JAMA Oncol. 2018;4(8):e174504. doi:10.1001/jamaoncol.2017.4504

This study uses data from the National Cancer Database to estimate utilization rates and factors associated with chemotherapy and radiation therapy delivery for limited-stage small cell lung cancer.

Research Letter

Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1123-1124. doi:10.1001/jamaoncol.2017.3993

This study investigates the association between immunotherapy and symptomatic radiation necrosis in patients with melanoma, non–small-cell lung cancer, or renal cell carcinoma and newly diagnosed brain metastases treated with stereotactic radiation therapy.

Change in Diagnostic Criteria for Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1125-1126. doi:10.1001/jamaoncol.2018.1446

This review of medical literature examines the criteria for diagnosis of noninvasive follicular thyroid neoplasm with papillarylike nuclear features.

Preferred Clinician Communication About Stopping Cancer Screening Among Older US Adults: Results From a National Survey

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1126-1128. doi:10.1001/jamaoncol.2018.2100

This cross-sectional survey study investigates how older US adults want their health care clinicians to frame discussions about stopping routine cancer screening.

Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1129-1130. doi:10.1001/jamaoncol.2018.2442

This population-based study investigates the survival and causes of death in patients with pancreatic adenocarcinoma to 21 years after diagnosis.

Health Barriers and Patterns of Gastric Cancer Care in Rural Central American Resource-Limited Settings

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1131-1133. doi:10.1001/jamaoncol.2018.2570

This population-based, case-control study analyzes the potential barriers to cancer care resources in rural Honduras in a cohort of patients with gastric cancer.

JAMA Network Insights

Management of Relapsed and Refractory Hodgkin Lymphoma in 2018

Abstract Full Text
JAMA Oncol. 2018;4(8):1120-1121. doi:10.1001/jamaoncol.2018.1767

This Insights discusses management strategies for relapsed and refractory Hodgkin lymphoma using the most recent therapeutic options.

JAMA Oncology Clinical Challenge

Hypopigmented Skin Lesions After Immunotherapy

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(8):1118-1119. doi:10.1001/jamaoncol.2018.0186

A woman in her 30s with metastatic soft tissue sarcoma being treated with nivolumab presented with diffuse macular cutaneous eruption and pruritus. What is your diagnosis?

Viewpoint

Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials

Abstract Full Text
JAMA Oncol. 2018;4(8):1041-1042. doi:10.1001/jamaoncol.2018.1002

This Viewpoint examines ethical concerns with respect to biopsy procedures performed in clinical trials and proposes a set of recommendations for biopsy results reporting.

The Affordable Care Act and Adolescents and Young Adults With Cancer: Much Progress, but Challenges Remain

Abstract Full Text
JAMA Oncol. 2018;4(8):1043-1044. doi:10.1001/jamaoncol.2018.1083

This Viewpoint examines the challenges facing US adolescents and young adult patients with cancer and access to insurance coverage since the 2010 Patient Protection and Affordable Care Act.

The Urgent Need in Oncology for a Comprehensive Cost of Care Task Force

Abstract Full Text
JAMA Oncol. 2018;4(8):1045-1046. doi:10.1001/jamaoncol.2018.1898

This Viewpoint describes the increasing imbalance in health care costs and health coverage in oncology and suggests a strategy to develop a comprehensive cost of care task force.

Editorial

Prostate Cancer Screening—A New Recommendation for Meaningful Physician-Patient Conversations

Abstract Full Text
JAMA Oncol. 2018;4(8):1049-1050. doi:10.1001/jamaoncol.2018.1492
Invited Commentary

Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia

Abstract Full Text
JAMA Oncol. 2018;4(8):1110-1111. doi:10.1001/jamaoncol.2017.4724

Efficacy and Toxic Effects of Cancer Immunotherapy Combinations—A Double-edged Sword

Abstract Full Text
JAMA Oncol. 2018;4(8):1116-1117. doi:10.1001/jamaoncol.2017.4606

Circulating Tumors Cells as a Biomarker of Radiation Benefit

Abstract Full Text
online only
JAMA Oncol. 2018;4(8):e180194. doi:10.1001/jamaoncol.2018.0194
Editor's Note

Conditional Survival as a Pragmatic Resource for Cancer Survivors and Health Care Professionals

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1130-1131. doi:10.1001/jamaoncol.2018.2895
Cancer Care Chronicles

Refusing to Become a “Potted Plant”

Abstract Full Text
JAMA Oncol. 2018;4(8):1047-1048. doi:10.1001/jamaoncol.2017.5833

This article describes the experience of a physician in the Netherlands who has performed euthanasia at the request of a patient.

Comment & Response

Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer

Abstract Full Text
JAMA Oncol. 2018;4(8):1133. doi:10.1001/jamaoncol.2018.0748

Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(8):1133-1134. doi:10.1001/jamaoncol.2018.0754

Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas

Abstract Full Text
JAMA Oncol. 2018;4(8):1134. doi:10.1001/jamaoncol.2018.0875

Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas—Reply

Abstract Full Text
JAMA Oncol. 2018;4(8):1134-1135. doi:10.1001/jamaoncol.2018.0895

Fiber Intake and Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2018;4(8):1135. doi:10.1001/jamaoncol.2018.0878

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

Abstract Full Text
JAMA Oncol. 2018;4(8):1135-1136. doi:10.1001/jamaoncol.2018.0881

Fiber Intake and Colorectal Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(8):1135. doi:10.1001/jamaoncol.2018.0901

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma—Reply

Abstract Full Text
JAMA Oncol. 2018;4(8):1136-1137. doi:10.1001/jamaoncol.2018.0898

Statistical Tests Used to Validate the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(8):1137. doi:10.1001/jamaoncol.2018.0884

Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis

Abstract Full Text
JAMA Oncol. 2018;4(8):1137-1138. doi:10.1001/jamaoncol.2018.1087

Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis—Reply

Abstract Full Text
JAMA Oncol. 2018;4(8):1138-1139. doi:10.1001/jamaoncol.2018.1105

Could Grape Seed Extract Be an Alternative Treatment in the Management of Hot Flashes?

Abstract Full Text
JAMA Oncol. 2018;4(8):1139. doi:10.1001/jamaoncol.2018.1090

Could Grape Seed Extract Be an Alternative Treatment in the Management of Hot Flashes?—Reply

Abstract Full Text
JAMA Oncol. 2018;4(8):1139. doi:10.1001/jamaoncol.2018.1108
Correction

Error in Figure Label and Caption

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1139. doi:10.1001/jamaoncol.2018.1995
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1035. doi:10.1001/jamaoncol.2017.3240
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(8):1127. doi:10.1001/jamaoncol.2017.3239
×